Home » Stocks » MTEM

Molecular Templates, Inc. (MTEM)

Stock Price: $8.69 USD -0.17 (-1.92%)
Updated December 2, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 434.19M
Revenue (ttm) 21.55M
Net Income (ttm) -92.35M
Shares Out 49.03M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 2
Last Price $8.69
Previous Close $8.86
Change ($) -0.17
Change (%) -1.92%
Day's Open 8.89
Day's Range 8.30 - 8.89
Day's Volume 256,110
52-Week Range 8.30 - 18.26

More Stats

Market Cap 434.19M
Enterprise Value 345.61M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 49.03M
Float n/a
EPS (basic) 2.04
EPS (diluted) -2.04
FCF / Share -1.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.90M
Short Ratio 4.48
Short % of Float n/a
Beta 1.56
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 20.15
PB Ratio 5.23
Revenue 21.55M
Operating Income -91.33M
Net Income -92.35M
Free Cash Flow -56.08M
Net Cash 88.58M
Net Cash / Share 1.77
Gross Margin -131.12%
Operating Margin -423.90%
Profit Margin -428.60%
FCF Margin -260.29%
ROA -43.48%
ROE -134.37%
ROIC -94.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 7
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$17.83*
(105.18% upside)
Low
13.0
Current: $8.69
High
22.0
Target: 17.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue22.2713.293.401.8876.9214.7212.505.870.06-
Revenue Growth67.63%291.31%80.59%-97.56%422.45%17.82%112.97%9362.9%--
Gross Profit22.2713.293.401.8876.9214.7212.505.870.06-
Operating Income-70.45-31.00-17.85-10.6226.93-31.25-26.02-20.00-30.04-23.91
Net Income-69.42-30.29-23.14-11.0343.82-21.58-28.42-71.14-25.65-18.68
Shares Outstanding37.7729.6011.400.216.395.495.264.934.173.06
Earnings Per Share1.861.022.11-59.045.94-5.39-5.39-14.41-6.16-6.16
EPS Growth82.35%-51.66%--------
Operating Cash Flow-25.24-4.47-14.26-9.03-38.00-27.7410.1529.91-23.85-22.38
Capital Expenditures-9.65-5.72-1.10-0.10-0.11-0.22-0.16-0.48-0.53-0.11
Free Cash Flow-34.89-10.19-15.37-9.13-38.11-27.969.9929.43-24.38-22.49
Cash & Equivalents12597.9658.911.7248.6858.6065.6770.8520.2915.17
Total Debt14.623.253.4812.88------
Net Cash / Debt11094.7055.43-11.1648.6858.6065.6770.8520.2915.17
Assets17414090.393.1053.6768.4010489.5222.4416.20
Liabilities71.1739.2513.1017.0312.8292.3712810317.9511.26
Book Value10310177.29-39.8140.85-23.98-23.48-13.854.484.94
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Molecular Templates, Inc.
Country United States
Employees 228
CEO Eric Poma

Stock Information

Ticker Symbol MTEM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MTEM

Description

Molecular Templates, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates, Inc. is headquartered in Austin, Texas.